Evidence map›Paper›PMID 34745964›Full record

ArticleFrontiers in oncology2021

Radiation Plus Anti-PD-1 Therapy for NSCLC Brain Metastases: A Retrospective Study.

Guixiang Liao, Yuting Qian, Sumbal Arooj, Zhihong Zhao, Maosheng Yan, Zihuang Li, Hongli Yang, Tao Zheng, Gang Li, Xianming Li and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Guixiang LiaoDepartment of Oncology, Shenzhen People's Hospital, The First Affiliated Hospital Of Southern University Of Science And Technology, Shenzhen, China.
Yuting QianDepartment of Radiation Oncology, Shenzhen People's Hospital, The Second College of Jinan University, Shenzhen, China.
Sumbal AroojDepartment of Oncology, Shenzhen People's Hospital, The First Affiliated Hospital Of Southern University Of Science And Technology, Shenzhen, China.
Zhihong ZhaoDepartment of Nephrology, Shenzhen People's Hospital, Second Clinical Medicine Centre, Jinan University, Shenzhen, China.
Maosheng YanDepartment of Oncology, Shenzhen People's Hospital, The First Affiliated Hospital Of Southern University Of Science And Technology, Shenzhen, China.
Zihuang LiDepartment of Oncology, Shenzhen People's Hospital, The First Affiliated Hospital Of Southern University Of Science And Technology, Shenzhen, China.
Hongli YangDepartment of Oncology, Shenzhen People's Hospital, The First Affiliated Hospital Of Southern University Of Science And Technology, Shenzhen, China.
Tao ZhengDepartment of Oncology, Shenzhen People's Hospital, The First Affiliated Hospital Of Southern University Of Science And Technology, Shenzhen, China.
Gang LiDepartment of Chemoradiation Oncology, The First Affiliated Hospital Of Wenzhou Medical University, Wenzhou, China.
Xianming LiDepartment of Oncology, Shenzhen People's Hospital, The First Affiliated Hospital Of Southern University Of Science And Technology, Shenzhen, China.
Muhammad KhanDepartment of Oncology, Shenzhen People's Hospital, The First Affiliated Hospital Of Southern University Of Science And Technology, Shenzhen, China.
Southern University of Science and Technology · CNJinan University · CNAnhui Medical University · CNFirst Affiliated Hospital of Wenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRadiation therapy (RT) is the mainstay of brain metastases (BMs), and anti-PD-1 blockade has led to intracranial responses in non-small cell lung carcinoma (NSCLC) patients with BMs.

objectiveThis study aimed to evaluate the efficacy and safety of adding anti-PD-1 blockade to RT in the management of NSCLC patients with BM in terms of survival outcome. MATERIALS AND

methodsWe retrospectively reviewed 70 NSCLC patients with BMs who were treated with whole brain radiation therapy (WBRT) between January 2016 and January 2021. Of the 70 patients, 29 additionally received anti-PD-1 therapy within 30 days of WBRT initiation. Baseline characteristics of the patients and efficacy outcomes such as progression-free survival (PFS) and overall survival (OS) were statistically compared using SPSS v26. Results were obtained using the Chi-square test/Fisher exact test, t-test, Kaplan-Meier, and Cox regression survival analyses.

resultsThe median survival for the entire cohort was 24 months (95% CI, 19.5-28.5). The median survival times for WBRT alone and WBRT plus anti-PD-1 therapy cohorts were 20 months (95% CI, 11.6-28.3) and 27 months (95% CI, 19.5-28.5), respectively (

conclusionsNSCLC patients with BM receiving additional anti-PD-1 therapy may derive better OS than WBRT alone without any increase in adverse events. Prospective well-designed studies are warranted to validate and elucidate the additive effects of the two modalities in this group of patients.

Indexed as

anti-PD-1 immunotherapybrain metastasis (BM)immune checkpoint blockade (ICB)immunotherapy (IT)non-small cell lung cancer (NSCLC)whole brain radiation therapy (WBRT)

Identifiers

PMID34745964
PMCPMC8567143
OpenAlexW3210459075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.